Recombinant modified fibroblast growth factors and therapeutic uses thereof
AssigneeTrefoil Therapeutics, Inc.
InventorsDavid Eveleth, Jennifer Jenkins-Eveleth, Amuthakannan Subramaniam, Ralph Bradshaw
Life of this patent
Estimating the term…
Abstract
Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration of FGFs.
Claims14
A method of ameliorating a corneal herpetic keratopathy or suppressing reactivation of a latent herpes virus comprising administering to an eye of a mammal, a pharmaceutical composition comprising a recombinant modified FGF-1 polypeptide comprising a sequence comprising mutated residues compared to wild-type FGF-1 sequence of SEQ ID NO:
- 1,
- wherein the mutated residues comprise Cys16Ser, Ala66Cys, and Cys117Val,
- wherein the polypeptide comprises an N-terminal methionine residue positioned upstream to the first residue of SEQ ID NO:
- 1,
- wherein the corneal herpetic keratopathy is secondary to an infection by a herpes virus;
- and
- wherein administering the pharmaceutical composition comprising the recombinant modified FGF-1 polypeptide results in suppression of reactivation of the latent herpes virus in the mammal.
Dependencies are inferred from the claim text.